Evidence for activity of GBR 830 (Anti-OX40) in extrinsic and intrinsic atopic dermatitis (AD): Post hoc analysis of a phase 2a study

Background: GBR 830 is a first-in-class, humanized, monoclonal immunoglobulin G1 antibody that selectively blocks the binding of OX40 to its OX40L ligand, thereby reducing the longevity and efficacy of effector and memory T cells. By blocking the OX40/OX40L pathway, GBR 830 has the potential to treat various T cell-mediated autoimmune diseases, including atopic dermatitis (AD). Topline results from a phase 2a study (NCT02683928) of adults with moderate-to-severe AD demonstrated that GBR 830 was safe and well tolerated.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research